Compass Pathways to report Q2, first-half results, host conference callPUBT·2 days ago, 05:31 AMCMPS-2.59%
Industrial Mega-Deals and Retail Restructurings Highlight Divergent 2026 PathsGlobal Report·Jul 21 at 04:13 AMNAKA-5.25%LRLCY-2.02%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN-1.67%CRSP-1.52%
Navigating the 2026 Economy: How AI and Resource Scarcity Are Rewiring Corporate StrategyGlobal Report·Jul 15 at 04:13 AMHAS+7.00%EH-1.93%
9 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·Jul 9 at 12:35 PMCAPR+3.41%LLY-2.85%
Analyst Reaffirms Buy on CMPS, Viewing Post-Data Pullback as Entry Opportunity Ahead of 1H27 LaunchTip Ranks·Jul 7 at 02:45 PMCMPS-2.59%
4 stocks to watch on Tuesday: CMPS, CRM, SNPS, ADSKbusinessinsider·Jul 7 at 08:15 AMADSK-2.47%SNPS+1.64%
Compass Pathways says Phase 3 COMP006 study shows COMP360 psilocybin maintains benefit through week 26 in TRDPUBT·Jul 7 at 05:30 AMCMPS-2.59%
Compass Pathways publishes investor deck on COMP360 psilocybin therapy for treatment-resistant depression approval pathPUBT·Jul 7 at 07:08 AMCMPS-2.59%
Compass gains on new late-stage trial data for psychedelic therapy in depressionbusinessinsider·Jul 7 at 06:30 AMCMPS-2.59%
